DAE HWA was established in 1984 with the vision of pursuing the happiness of mankind. With the completion of the cGMP facilities in 2009, we are striving to produce high quality medicines.

Currently, we are producing 150 kinds of medicine and supplying to around 3,000 hospitals nationally as well as conducting business with around 6,000 pharmacies.

Our lipids-based oral formulation technology is an outstanding global leading technology. DHP107, an oral paclitaxel formula, is mainly composed of edible oils and does not need co-administration of an absorption enhancer or efflux pump inhibitor.

Ongoing phase 3 clinical trial will be completed soon and DAE HWA is expecting first approval of oral paclitaxel form in the world. Also, we have plan for worldwide clinical development and commercialization with a collaboration or partnership.

DAE HWA is continuing our research on transdermal drug delivery system (TDDS) technology. Moreover, we are developing a new platform technology for Orally Disintegration Film (ODF) products. Also, DAE HWA is focusing on the developing of innovative herbal products both as medicines and functional foods for cardiovascular, neurological area.

As well as the release of Kebanon, Loxona, Plocfen, Hyemingo, DDL (NSAIDs medication), Resnalin (asthma medications, 2010), Duphenyl (narcotic analgesics, 2014) and Rivamensa (dementia medication, 2014), we are understudying to release reformulated NSAIDs, incontinence medicines, antihistamine medications, antidepressants, antivirus medicine, CSN medication etc. using TDDS/ODF technology and developing new herbal medicine & functional food for Alzheimer’s and Parkinson’s disease.